We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MYOR:IDXPT Mayora Indah Tbk Analysis

Data as of 2026-07-09 - not real-time

IDR 1,730.00

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Mayora’s shares are trading at IDR 1,730, well below the 30‑day DCF fair value of IDR 2,394, implying a potential upside of over 50 %. The price sits beneath the 20‑day SMA (IDR 1,794) and the 50‑day SMA (IDR 1,786), while the MACD line remains deeply negative (-11.39) against a flat signal line, signalling bearish momentum in the short run. However, the RSI at 44 suggests the stock is not yet oversold, and the neutral trend line indicates no decisive directional bias at present. Volume is on a decreasing trajectory, which may limit short‑term price swings, but the beta of 0.22 points to low systematic risk. On the fundamentals side, Mayora delivers a solid 3.48 % dividend yield with a modest 39 % payout ratio, strong operating cash flow (IDR 5.6 tn) and free cash flow (IDR 4.1 tn), and a healthy ROE of 17 %. The company’s PE of 12.4x and forward PE of 10.8x are attractive relative to its peers, while the price‑to‑book of 2.0x aligns with its asset base. The fear‑greed index sits at “Extreme Greed” (93.14), reflecting strong market appetite for risk‑on assets, which could further buoy demand for undervalued defensive stocks like Mayora.
Overall, the valuation gap, robust cash generation, and sustainable dividend make Mayora an appealing value play, though the current technical setup advises caution. Investors should monitor the support at IDR 1,605 and the resistance near IDR 1,990, while keeping an eye on volume trends and any macro‑economic shifts in Indonesia that could affect consumer spending.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram
  • Price below 20‑day SMA
  • Decreasing trading volume

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF upside of >50 %
  • Strong cash flow and low debt ratio
  • Attractive dividend yield with sustainable payout

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Defensive consumer staples positioning
  • Consistent profitability and ROE
  • Long‑term valuation gap relative to fair value

Key Metrics & Analysis

Financial Health

Revenue Growth-4.70%
Profit Margin8.17%
P/E Ratio12.4
ROE17.13%
ROA8.78%
Debt/Equity26.63
P/B Ratio2.0
Op. Cash FlowIDR5617.7B
Free Cash FlowIDR4064.8B

Technical Analysis

TrendNeutral
RSI44.3
SupportIDR 1,605.00
ResistanceIDR 1,990.00
MA 20IDR 1,794.25
MA 50IDR 1,786.20
MA 200IDR 2,017.30
MACDBearish
VolumeDecreasing
Fear & Greed Index93.14

Valuation

Fair ValueIDR 2,394.09
Target PriceIDR 2,630.00
Upside/Downside52.02%
GradeUndervalued
TypeValue
Dividend Yield3.48%

Risk Assessment

Beta0.22
Volatility55.60%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.